• SUBSCRIBE
    • Action Alerts PLUS
    • Real Money
    • Real Money Pro
    • Quant Ratings
    • Retirement Daily
    • Stocks Under $10
    • Trifecta Stocks
    • Top Stocks
    • Real Money Pro Portfolio
    • Chairman's Club
    • Compare All
  • JIM CRAMER
    • Action Alerts PLUS
    • Cramer's Blog
    • Cramer's Monthly Call
    • Jim Cramer's Best Stocks
    • Cramer's Articles
    • Mad Money
    • 25 Rules for Investing
    • 10 Commandments
  • INVESTING
    • Bitcoin
    • Cannabis
    • Cryptocurrency
    • ETFs
    • Earnings
    • Fixed Income
    • Funds
      • Bond Funds
      • Index Funds
      • Mutual Funds
    • Futures
    • Options
    • REITs
    • Stocks
      • Penny Stocks
      • Preferred Stocks
  • PERSONAL FINANCE
    • Credit Cards
    • Debt Management
    • Education
    • Employee Benefits
    • Insurance
      • Car Insurance
      • Disability Insurance
      • Health Insurance
      • Home Insurance
      • Life Insurance
    • Mortgages
    • Real Estate
    • Savings
    • Taxes
  • RETIREMENT
    • 401K
    • Estate Planning
    • IRAs
      • Roth IRAs
    • Social Security
  • TECHNOLOGY
    • Cybersecurity
  • MARKETS
    • Bankruptcy
    • Commodities
      • Gold
      • Oil
    • Corporate Governance
    • Currencies
    • Emerging Markets
    • IPOs
    • Mergers and Acquisitions
    • Rates and Bonds
      • Junk Bonds
      • Treasury Bonds
    • Regulation
  • HOW-TO
  • VIDEO
    • Audio
  • Courses
    • Personal Finance Essentials
    • Fundamentals of Investing
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
  • Privacy Settings
  • Logo
  • JIM CRAMER
  • INVESTING
  • PERSONAL FINANCE
  • RETIREMENT
  • TECHNOLOGY
  • MARKETS
  • HOW-TO
  • VIDEO
  • COURSES
Login
Account
TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
  • Alerts
  • |
  • Newsletters
  • Logo
  • JIM CRAMER
  • INVESTING
  • PERSONAL FINANCE
  • RETIREMENT
  • TECHNOLOGY
  • MARKETS
  • HOW-TO
  • VIDEO
  • COURSES
Login
Account

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest
STOCKS

Biotech Stock Mailbag: Idenix vs. Pharmasset?

  • By Adam Feuerstein
  • Oct 21, 2011 8:12 AM EDT
J.P. Morgan Healthcare Confab Live Blog: Day Two
INVESTING

Biotech Stock Live Chat

  • By Adam Feuerstein
  • Oct 20, 2011 11:59 AM EDT
AirMedia Group (AMCN) In A Perilous Reversal
MARKETS

Neoprobe Stock Gaps Up On Today's Open (NEOP)

  • By TheStreet Wire
  • Oct 20, 2011 9:54 AM EDT
First-Quarter Sales of Bristol-Myers' Cancer Immunotherapy Drug Miss Street Forecast
STOCKS

Neoprobe Proves A Short Seller Wrong

  • By Adam Feuerstein
  • Oct 20, 2011 7:58 AM EDT
Jones Lang LaSalle (JLL) Reaches New Lifetime High Today
MARKETS

Neoprobe Stock Gaps Up On Today's Open (NEOP)

  • By TheStreet Wire
  • Sep 8, 2011 9:55 AM EDT
Shire Rises After Analyst Predicts Allergan Takeover
STOCKS

Biotech Stock Mailbag: Cyclacel Pharma

  • By Adam Feuerstein
  • Aug 12, 2011 5:19 AM EDT
Today's Weak On High Volume Stock: Ocean Rig UDW (ORIG)
MARKETS

Neoprobe Stock Gaps Up On Today's Open (NEOP)

  • By TheStreet Wire
  • Aug 11, 2011 10:00 AM EDT
Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: SBW, HIO, ETG
MARKETS

Neoprobe Stock Soars (NEOP)

  • By TheStreet Wire
  • Aug 9, 2011 4:19 PM EDT
Galapagos Receives a Rousing Welcome on Its First Day of Trading
STOCKS

Amag: Hedge Fund Makes Takeover Bid

  • By Adam Feuerstein
  • Aug 3, 2011 8:55 AM EDT
One Short Seller's Take On Arena's Slow Belviq Launch
STOCKS

10 Biotech Trades for Second Half of 2011

  • By Adam Feuerstein
  • Jul 6, 2011 12:24 PM EDT
J.P. Morgan Healthcare Confab Live Blog: Day Two
INVESTING

Biotech Stock Mailbag: Live Chat

  • By Adam Feuerstein
  • Jun 17, 2011 11:59 AM EDT
AbbVie Deserves More Respect
STOCKS

Neoprobe v. Short Seller Over Lymphoseek

  • By Adam Feuerstein
  • Jun 13, 2011 7:37 AM EDT
Mannkind Afrezza FDA Panel Live Blog
INVESTING

ASCO 2011 Live Blog: Monday

  • By Adam Feuerstein
  • Jun 6, 2011 12:28 PM EDT
Galapagos Receives a Rousing Welcome on Its First Day of Trading
STOCKS

Biotech Stock Mailbag: Fibrocell Science

  • By Adam Feuerstein
  • May 27, 2011 6:00 AM EDT
One Short Seller's Take On Arena's Slow Belviq Launch
STOCKS

Cancer Stocks on Tap: ASCO Abstract Preview

  • By Adam Feuerstein
  • May 11, 2011 7:18 AM EDT
Merck Sales of New Cancer Immunotherapy Top Street Estimates
STOCKS

Biotech Stock Mailbag: Neoprobe

  • By Adam Feuerstein
  • May 6, 2011 7:00 AM EDT
Grom Social Offers a Safe Alternative to Facebook for Young People
PERSONAL FINANCE

Top Stocks Under $5 Beating the Market

  • By Robert Holmes
  • Feb 24, 2011 6:30 AM EST
'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab
STOCKS

Biotech Mailbag: BIO CEO Wrap

  • By Adam Feuerstein
  • Feb 18, 2011 7:00 AM EST
Grom Social Offers a Safe Alternative to Facebook for Young People
INVESTING

BIO CEO Conference Live Blog: Day 2

  • By Adam Feuerstein
  • Feb 15, 2011 3:55 PM EST
Abbott Goes After Endometriosis
STOCKS

Rodman Rambles: Promising Biotechs

  • By Adam Feuerstein
  • Sep 15, 2010 10:28 AM EDT
MARKETS

Double-Witching Puts a Positive Spell on the Markets

  • By Joe Bousquin
  • Nov 21, 1997 6:45 PM EST
MARKETS

Stocks Drift Higher on Light Volume

  • By Joe Bousquin
  • Oct 13, 1997 6:50 PM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2019 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.